Beta-Blockers and Hypoglycemia Risk

Introduction to Beta-Blocker Risks

The European Society of Cardiology recommends that beta-blockers be used with caution in diabetic patients, as they can mask the warning symptoms of hypoglycemia, making it harder to detect and potentially more dangerous, particularly in insulin-dependent diabetics 1.
Non-selective beta-blockers like propranolol carry a significantly higher risk than cardioselective agents like metoprolol for both prolonging hypoglycemia and causing severe episodes 1, 2.

Beta-blockers alter counter-regulatory responses to hypoglycemia by blocking the typical adrenergic warning signs, such as tremor, palpitations, and tachycardia, that patients normally rely on to recognize low blood sugar 1, 2.
The American Heart Association notes that sweating is paradoxically increased or preserved during hypoglycemia with beta-blocker use, as this response is mediated through cholinergic rather than beta-adrenergic pathways 2.

The European Society of Cardiology guidelines state that elderly diabetic patients on insulin experienced a relative risk of 2.16 for serious hypoglycemia with non-selective beta-blockade like propranolol 1.
The American College of Cardiology recommends that beta-1 selective agents like metoprolol and atenolol be preferred over non-selective agents in diabetic patients, as they carry a lower risk of serious hypoglycemia 1.

The American Diabetes Association notes that type 1 diabetics or insulin-treated type 2 diabetics with deficient glucagon responses are at highest risk because they depend entirely on epinephrine-mediated beta-adrenergic mechanisms for hypoglycemia recovery 3.
The Journal of the American College of Cardiology states that patients with "brittle" diabetes or labile blood glucose control require special caution when using beta-blockers 5, 6.

The European Society of Cardiology recommends that cardioselective beta-1 agents be preferred over non-selective agents in all diabetic patients, and that vasodilating beta-blockers be chosen for patients with metabolic syndrome or established diabetes 1, 2, 4.
The American Heart Association suggests that patients be warned that typical hypoglycemia warning signs will be blunted or absent, and that sweating may be the primary remaining warning sign of hypoglycemia 2, 3.
The American College of Cardiology recommends that insulin or sulfonylurea doses be reduced when initiating beta-blocker therapy, and that close blood glucose monitoring be implemented for the first 3-4 weeks after beta-blocker initiation 5, 6.

The European Society of Cardiology guidelines provide the highest quality evidence, demonstrating clear differences in hypoglycemia risk between non-selective and cardioselective agents in large populations 1.
The American College of Cardiology notes that even cardioselective agents at therapeutic doses impair glucose recovery from hypoglycemia in insulin-dependent diabetes, so no beta-blocker is completely safe in this population 1.